Background: Despite standard statin therapy, a majority of patients retain a high “residual
risk” of cardiovascular events. Objectives: The aim of this study was to evaluate the effects of …

Background: There is no study focusing on changes in coronary atherosclerosis during dual
lipid-lowering therapy with statin and ezetimibe. Methods and Results: Eighty-nine patients …

Statins reduce both atherogenic lipoproteins and high-sensitivity C-reactive protein
(hsCRP). The optimal strategy for administration of lipid-lowering agents has evolved …

Background Statins reduce adverse cardiovascular outcomes and slow the progression of
coronary atherosclerosis in proportion to their ability to reduce low-density lipoprotein (LDL) …

Objectives: The objective of this study was to evaluate whether the regressive effects of
aggressive lipid-lowering therapy with atorvastatin on coronary plaque volume (PV) in …

ContextPrior intravascular ultrasound (IVUS) trials have demonstrated slowing or halting of
atherosclerosis progression with statin therapy but have not shown convincing evidence of …

Background: It has been suggested that intensive lipid-lowering therapy using statins
significantly decreases atheromatous plaque volume. The effect of rosuvastatin on plaque …

High-dose rosuvastatin induces regression of coronary atherosclerosis, but it remains
uncertain whether usual-dose statin has similar effects. We compared the effects of …

Background: The Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary
Syndrome (JAPAN-ACS) trial has found that early aggressive statin therapy in patients with …

Background—Recent clinical trials have demonstrated that aggressive lipid lowering by
statins could prevent recurrent events after acute coronary syndrome (ACS). We …